HOME > TOP STORIES
TOP STORIES
-
REGULATORY Vyvgart, Pivlaz to Be 1st to Face Zero Premium Rule for Low Cost Disclosures
April 12, 2022
-
REGULATORY Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
-
BUSINESS Astellas, GSK, 2 Other Firms Log 10%-Plus Drop in Workforce: Jiho Poll
April 11, 2022
-
REGULATORY MHLW Set to Boost Recognition of Reporting System for Improper Drug Promotions
April 8, 2022
-
BUSINESS New Grad Hiring Down 4.4% in Spring 2022, Downtrend for Sales Reps Continues: Poll
April 7, 2022
-
BUSINESS Jardiance Now Allowed for Use in HFpEF Patients: Label Update
April 7, 2022
-
BUSINESS Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
-
BUSINESS Pfizer Tops 2021 Global Pharma Ranking on Vaccine Boon: Jiho Tally
April 6, 2022
-
REGULATORY SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
-
ORGANIZATION JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
-
REGULATORY Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
-
ORGANIZATION Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
April 4, 2022
-
REGULATORY Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
-
BUSINESS COVID-19 as Catalyst for Introducing Decentralized Clinical Trials in Japan; Some Results Due Out by Year-End
April 1, 2022
-
REGULATORY Japan PM Touts Proposed Emergency Approval Scheme as Bill Enters Diet Deliberations
April 1, 2022
-
REGULATORY 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
-
BUSINESS Novartis Stepping Up Population Health Initiatives in CV, Oncology Arenas to Solve Regional Challenges
March 30, 2022
-
REGULATORY Japan Approves Kerendia, Vabysmo, Ondexxya, Takhzyro and More
March 29, 2022
-
REGULATORY Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
-
ORGANIZATION FPMAJ Begins Survey on Risk of Mineral Resource Shortages amid Ukraine War
March 28, 2022
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
